YESIDE OJO: Open Payments
NPI 1760934913 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$835 in 35 payments from 11 companies in 2025. Trend: 2023 $604 · 2024 $382 · 2025 $835
Food & beverage: $835
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $285 |
| Otsuka America Pharmaceutical, Inc. | 4 | $185 |
| Vanda Pharmaceuticals Inc. | 3 | $75 |
| Lundbeck LLC | 3 | $69 |
| Tris Pharma Inc | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Alkermes, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| TMS NeuroHealth Centers Inc. | 1 | $23 |
Products named: VRAYLAR, ABILIFY MAINTENA, REXULTI, HETLIOZ, Dyanavel XR, CAPLYTA, TRINTELLIX, ARISTADA.
Industry payments across MD — which companies pay providers there.
